Sector News

UCB, Advent, Avista End Acquisition Agreement

December 17, 2014
Life sciences
Belgian pharmaceutical company UCB SA (UCB.BT), Advent International and Avista Capital Partners ended an acquisition agreement that would have seen Advent and Avista buy UCB’s U.S.-based speciality generics subsidiary for $ 1.5 billion, the company said in a press release.
 
UCB said it still plans to divest the generics unit, Kremers Urban Pharmaceutical Inc. It said the decision to terminate the acquisition agreement, which was signed last month, was a result of an “unexpected conflict” between the timing of the deal and a regulatory process launched in the U.S.
 
On Nov. 14, Kremers Urban said it had been informed by the U.S. Food and Drug Administration that the agency wanted an additional study on one of the company’s products–the methylphenidate hydrochloride extended-release (ER) tablet.
 
“While we are working on clarifying the situation around methylphenidate ER we will continue the divestiture process for Kremers Urban,” said Detlef Thielgen, Chief Financial Officer of UCB.
 
UCB said Tuesday’s announcement doesn’t impact the company’s most recent 2014 financial outlook, with the firm contining to expect total revenue of EUR3.15 billion-EUR3.25 billion ($3.94 billion-$4.07 billion) and underlying profits of EUR590 million to EUR620 million.
 
UCB’s shares closed 0.6% higher at EUR64.06.
 
By Laurence Norman
 
Source: Dow Jones Business News

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend